La Jolla Story

<div class='circular--portrait' style='background:#754DEB;color: #F0FFF0;font-size:4em;'>LJ</div>
LJPC -- USA Stock  

USD 4.98  0.11  2.26%

La Jolla Revenue Per Employee is projected to increase significantly based on the last few years of reporting. The past year's Revenue Per Employee was at 253,341. The current year Enterprise Value is expected to grow to about 29 M, whereas Net Income Per Employee is forecasted to decline to (1.4 M). The primary aim of this article is to break down La Jolla potential for December. We are going to analyze if La Jolla is reasonably priced going into December.
Published over three weeks ago
View all stories for La Jolla | View All Stories
What are the La Jolla (NASDAQ:LJPC) projections for December
La Jolla has performance score of 1 on a scale of 0 to 100. The company owns a Beta (Systematic Risk) of -0.718, which conveys possible diversification benefits within a given portfolio. Let's try to break down what La Jolla's beta means in this case. As returns on the market increase, returns on owning La Jolla are expected to decrease at a much lower rate. During the bear market, La Jolla is likely to outperform the market. Although it is extremely important to respect La Jolla Pharmaceutical existing price patterns, it is better to be realistic regarding the information on equity price patterns. The approach towards estimating future performance of any stock is to evaluate the business as a whole together with its past performance, including all available fundamental and technical indicators. By reviewing La Jolla Pharmaceutical technical indicators, you can at this time evaluate if the expected return of 0.0742% will be sustainable into the future. La Jolla Pharmaceutical at this moment owns a risk of 4.22%. Please verify La Jolla Pharmaceutical potential upside, rate of daily change, and the relationship between the sortino ratio and skewness to decide if La Jolla Pharmaceutical will be following its current price history.
There are currently many different techniques concerning forecasting the market as a whole as well as predicting future values of individual securities such as La Jolla Pharmaceutical. Regardless of method or technology, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.

Predictive Modules for La Jolla


How important is La Jolla's Liquidity

La Jolla financial leverage refers to using borrowed capital as a funding source to finance La Jolla Pharmaceutical ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. La Jolla financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between La Jolla's total debt and its cash.

How La Jolla utilizes its cash?

To perform a cash flow analysis of La Jolla, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash La Jolla is receiving and how much cash it distributes out in a given period. The La Jolla cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. La Jolla Net Cash Flow from Operations is projected to decrease significantly based on the last few years of reporting. The past year's Net Cash Flow from Operations was at (84.95 Million)

Acquisition by Hearne Michael S of 134 shares of La Jolla subject to Rule 16b-3

Legal trades by La Jolla insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
La Jolla insider trading alert for grant of employee stock option (right to buy) by Hearne Michael S, Chief Financial Officer, on 2nd of December 2020. This event was filed by La Jolla Pharmaceutical C with SEC on 2020-12-02. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

A Deeper look at La Jolla

La Jolla Pharmaceutical exhibits very low volatility with skewness of 0.13 and kurtosis of 0.53. However, we advise investors to further study La Jolla Pharmaceutical technical indicators to make sure all market info is available and is reliable.

Returns Breakdown

Return on Investment(387.97)
Return on Assets(0.79)
Return on Equity5.44
Return Capital(2.14)
Return on Sales(4.95)

Will La Jolla continue to go out of control?

The market risk adjusted performance is down to 0.2 as of today. As of the 8th of November, La Jolla owns the Market Risk Adjusted Performance of 0.203, mean deviation of 3.33, and Standard Deviation of 4.44. Concerning fundamental indicators, the technical analysis model lets you check potential technical drivers of La Jolla Pharmaceutical, as well as the relationship between them. Strictly speaking, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume patterns, or the prices will eventually revert. We were able to break down and interpolate data for nineteen technical drivers for La Jolla, which can be compared to its peers in the sector. Please verify La Jolla Pharmaceutical jensen alpha, and the relationship between the coefficient of variation and potential upside to decide if La Jolla Pharmaceutical is priced favorably, providing market reflects its prevailing price of 3.57 per share. Given that La Jolla Pharmaceutical has jensen alpha of (0.12), we recommend you to check La Jolla's latest market performance to make sure the company can sustain itself at some future date.

The Bottom Line

Whereas other entities within the biotechnology industry are still a little expensive, even after the recent corrections, La Jolla may offer a potential longer-term growth to investors. The inconsistency in the assessment between current La Jolla valuation and our trade advice on La Jolla is due to the recent market swings and your selection of investing horizon. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to La Jolla.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Gabriel Shpitalnik do not own shares of La Jolla Pharmaceutical. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com